BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates through two segments: BRAINBiocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients, and BRAINBioIncubator, which covers a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds for foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications at chemical companies, waste and hazardous materials disposal, and energy and raw materials production. Formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG, it changed its name to BRAIN Biotech AG in April 2021, was founded in 1993, and is headquartered in Zwingenberg, Germany.

0RFI.LSE▲

BRAIN Biotech Appoints Dr. Sven K. Weber as New CEO

BRAIN Biotech AG has appointed Dr. Sven K. Weber as its new CEO, effective October 1, 2026, succeeding Adriaan Moelker who will step down on September 30 after six years in the role. Dr. Weber, 44, joins from BASF Group where he most recently served as Vice President responsible for the global enzyme business, having previously held leadership roles at Chemetall GmbH and hte GmbH. Supervisory Board Chairman Dr. Michael Majerus thanked Moelker for repositioning the company as an integrated enzyme manufacturer and expressed confidence that Dr. Weber will accelerate growth and strengthen profitability. Dr. Weber stated his goal is to develop BRAIN into a leading provider of specialty enzymes in selected application areas and to tap additional growth potential through the BRAINBioIncubator.

BNN.XETRA ▲

NewMediaWire·51dRead more →